BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

6-sialyllactose ameliorates dihydrotestosterone-induced benign prostatic hyperplasia through suppressing VEGF-mediated angiogenesis

  • Kim, Eun-Yeong (Department of Korean Medical Science, School of Korean Medicine, Pusan National University) ;
  • Jin, Bo-Ram (Department of Pharmacology, College of Korean Medicine, Sangji University) ;
  • Chung, Tae-Wook (Korean Medical Research Center for Healthy Aging, Pusan National University) ;
  • Bae, Sung-Jin (Korean Medical Research Center for Healthy Aging, Pusan National University) ;
  • Park, Hyerin (Department of Korean Medical Science, School of Korean Medicine, Pusan National University) ;
  • Ryu, Dongryeol (Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine) ;
  • Jin, Ling (Department of Korean Medical Science, School of Korean Medicine, Pusan National University) ;
  • An, Hyo-Jin (Department of Pharmacology, College of Korean Medicine, Sangji University) ;
  • Ha, Ki-Tae (Department of Korean Medical Science, School of Korean Medicine, Pusan National University)
  • Received : 2019.04.20
  • Accepted : 2019.07.13
  • Published : 2019.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Benign prostatic hyperplasia (BPH), a common disease in elderly males, is accompanied by non-malignant growth of prostate tissues, subsequently causing hypoxia and angiogenesis. Although VEGF-related angiogenesis is one of the therapeutic targets of prostate cancer, there is no previous study targeting angiogenesis for treatment of BPH. Dihydrotestosterone (DHT)-induced expressions of vascular endothelial growth factor (VEGF) in prostate epithelial RWPE-1 cells and human umbilical vascular endothelial cells (HUVECs). Conditioned media (CM) from DHT-treated RWPE-1 cells were transferred to HUVECs. Then, 6SL inhibited proliferation, VEGFR-2 activation, and tube formation of HUVECs transferred with CM from DHT-treated RWPE-1 cells. In the rat BPH model, 6SL reduced prostate weight, size, and thickness of the prostate tissue. Formation of vessels in prostatic tissues were also reduced with 6SL treatment. We found that 6SL has an ameliorative effect on in vitro and in vivo the BPH model via inhibition of VEGFR-2 activation and subsequent angiogenesis. These results suggest that 6SL might be a candidate for development of novel BPH drugs.

Keywords

References

  1. Emberton M, Andriole GL, de la Rosette J et al (2003) Benign prostatic hyperplasia: a progressive disease of aging men. Urology 61, 267-273 https://doi.org/10.1016/S0090-4295(02)02371-3
  2. O'Leary MP (2003) Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications. Urology 62, 15-23 https://doi.org/10.1016/S0090-4295(03)00480-1
  3. Keledjian K, Borkowski A, Kim G et al (2001) Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. Prostate 48, 71-78 https://doi.org/10.1002/pros.1083
  4. Carson C 3rd, Rittmaster R (2003) The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 61, 2-7 https://doi.org/10.1016/S0090-4295(03)00045-1
  5. Zaman Huri H, Hui Xin C, Sulaiman CZ (2014) Drug-related problems in patients with benign prostatic hyperplasia: a cross sectional retrospective study. PLoS One 9, e86215 https://doi.org/10.1371/journal.pone.0086215
  6. DuBeau CE, Resnick NM (1992) Controversies in the diagnosis and management of benign prostatic hypertrophy. Adv Intern Med 37, 55-83
  7. Chung KJ, Chung BI (2017) Expected next-generation drugs under development in relation to voiding symptoms. Int Neurourol J 21, 97-101 https://doi.org/10.5213/inj.1734928.464
  8. McNeal JE (1978) Origin and evolution of benign prostatic enlargement. Invest Urol 15, 340-345
  9. Lekas A, Lazaris AC, Deliveliotis C et al (2006) The expression of hypoxia-inducible factor-1alpha (HIF-1alpha) and angiogenesis markers in hyperplastic and malignant prostate tissue. Anticancer Res 26, 2989-2993
  10. Wu F, Ding S, Li X et al (2016) Elevated expression of HIF-lalpha in actively growing prostate tissues is associated with clinical features of benign prostatic hyperplasia. Oncotarget 7, 12053-12062 https://doi.org/10.18632/oncotarget.7641
  11. Pareek G, Shevchuk M, Armenakas NA et al (2003) The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol 169, 20-23 https://doi.org/10.1016/S0022-5347(05)64025-6
  12. Stefanou D, Batistatou A, Kamina S, Arkoumani E, Papachristou DJ, Agnantis NJ (2004) Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in benign prostatic hyperplasia and prostate cancer. In Vivo 18, 155-160
  13. Aweimer A, Stachon T, Tannapfel A, Koller M, Truss MC, Stachon A (2012) Regulation of soluble VEGFR-2 secreted by microvascular endothelial cells derived from human BPH. Prostate Cancer Prostatic Dis 15, 157-164 https://doi.org/10.1038/pcan.2011.63
  14. Berger AP, Kofler K, Bektic J et al (2003) Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia. Prostate 57, 57-65 https://doi.org/10.1002/pros.10279
  15. Jackson MW, Bentel JM, Tilley WD (1997) Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 157, 2323-2328 https://doi.org/10.1016/S0022-5347(01)64774-8
  16. Lekas AG, Lazaris AC, Chrisofos M et al (2006) Finasteride effects on hypoxia and angiogenetic markers in benign prostatic hyperplasia. Urology 68, 436-441 https://doi.org/10.1016/j.urology.2006.03.038
  17. Sordello S, Bertrand N, Plouet J (1998) Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens. Biochem Biophys Res Commun 251, 287-290 https://doi.org/10.1006/bbrc.1998.9328
  18. Levine AC, Liu XH, Greenberg PD et al (1998) Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. Endocrinology 139, 4672-4678 https://doi.org/10.1210/endo.139.11.6303
  19. Foo KT (2017) Pathophysiology of clinical benign prostatic hyperplasia. Asian J Urol 4, 152-157 https://doi.org/10.1016/j.ajur.2017.06.003
  20. Wen J, Zhao Y, Li J et al (2013) Suppression of DHT-induced paracrine stimulation of endothelial cell growth by estrogens via prostate cancer cells. Prostate 73, 1069-1081 https://doi.org/10.1002/pros.22654
  21. Wu S, Grimm R, German JB, Lebrilla CB (2011) Annotation and structural analysis of sialylated human milk oligosaccharides. J Proteome Res 10, 856-868 https://doi.org/10.1021/pr101006u
  22. Yonekawa T, Malicdan MC, Cho A et al (2014) Sialyllactose ameliorates myopathic phenotypes in symptomatic GNE myopathy model mice. Brain 137, 2670-2679 https://doi.org/10.1093/brain/awu210
  23. Bode L (2012) Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology 22, 1147-1162 https://doi.org/10.1093/glycob/cws074
  24. Chung TW, Kim EY, Kim SJ et al (2017) Sialyllactose suppresses angiogenesis by inhibiting VEGFR-2 activation, and tumor progression. Oncotarget 8, 58152-58162 https://doi.org/10.18632/oncotarget.16192
  25. Vaarala MH, Hirvikoski P, Kauppila S, Paavonen TK (2012) Identification of androgen-regulated genes in human prostate. Mol Med Rep 6, 466-472 https://doi.org/10.3892/mmr.2012.956
  26. Park SA, Jeong MS, Ha KT, Jang SB (2018) Structure and function of vascular endothelial growth factor and its receptor system. BMB Rep 51, 73-78 https://doi.org/10.5483/BMBRep.2018.51.2.233
  27. Li J, Tian Y, Guo S, Gu H, Yuan Q, Xie X (2018) Testosterone-induced benign prostatic hyperplasia rat and dog as facile models to assess drugs targeting lower urinary tract symptoms. PLoS One 13, e0191469 https://doi.org/10.1371/journal.pone.0191469
  28. Kim SK, Seok H, Park HJ et al (2015) Inhibitory effect of curcumin on testosterone induced benign prostatic hyperplasia rat model. BMC Complement Altern Med 15, 380 https://doi.org/10.1186/s12906-015-0825-y
  29. Minutoli L, Bitto A, Squadrito F et al (2013) Serenoa repens, lycopene and selenium: a triple therapeutic approach to manage benign prostatic hyperplasia. Curr Med Chem 20, 1306-1312 https://doi.org/10.2174/0929867311320100007
  30. Said MM, Hassan NS, Schlicht MJ, Bosland MC (2015) Flaxseed suppressed prostatic epithelial proliferation in a rat model of benign prostatic hyperplasia. J Toxicol Environ Health A 78, 453-465 https://doi.org/10.1080/15287394.2014.993779
  31. Kim JH, Baek MJ, Sun HY et al (2018) Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis. PLoS One 13, e0203479 https://doi.org/10.1371/journal.pone.0203479
  32. Jun JEJ, Kinkade A, Tung ACH, Tejani AM (2017) 5alpha-Reductase inhibitors for treatment of benign prostatic hyperplasia: A systematic review and metaanalysis. Can J Hosp Pharm 70, 113-119
  33. Thomas D, Chughtai B, Kini M, Te A (2017) Emerging drugs for the treatment of benign prostatic hyperplasia. Expert Opin Emerg Drugs 22, 201-212 https://doi.org/10.1080/14728214.2017.1369953
  34. Bostwick DG, Iczkowski KA (1998) Microvessel density in prostate cancer: prognostic and therapeutic utility. Semin Urol Oncol 16, 118-123
  35. Padhani AR, Harvey CJ, Cosgrove DO (2005) Angiogenesis imaging in the management of prostate cancer. Nat Clin Pract Urol 2, 596-607 https://doi.org/10.1038/ncpuro0356
  36. Ravindranath N, Wion D, Brachet P, Djakiew D (2001) Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J Androl 22, 432-443
  37. ten Bruggencate SJ, Bovee-Oudenhoven IM, Feitsma AL, van Hoffen E, Schoterman MH (2014) Functional role and mechanisms of sialyllactose and other sialylated milk oligosaccharides. Nutr Rev 72, 377-389 https://doi.org/10.1111/nure.12106
  38. Godoy A, Montecinos VP, Gray DR et al (2011) Androgen deprivation induces rapid involution and recovery of human prostate vasculature. Am J Physiol Endocrinol Metab 300, E263-275 https://doi.org/10.1152/ajpendo.00210.2010
  39. Chung HK, Ryu D, Kim KS et al (2017) Growth differentiation factor 15 is a myomitokine governing systemic energy homeostasis. J Cell Biol 216, 149-165 https://doi.org/10.1083/jcb.201607110
  40. Ryu D, Jo YS, Lo Sasso G et al (2014) A SIRT7-dependent acetylation switch of GABPbeta1 controls mitochondrial function. Cell Metab 20, 856-869 https://doi.org/10.1016/j.cmet.2014.08.001
  41. Chung TW, Kim SJ, Choi HJ et al (2013) CAPE suppresses VEGFR-2 activation, and tumor neovascularization and growth. J Mol Med (Berl) 91, 271-282 https://doi.org/10.1007/s00109-012-0952-6